Atossa Therapeutics shares climbed 10% pre-market after the FDA granted Orphan Drug Designation to its investigational therapy (Z)-Endoxifen for Duchenne Muscular Dystrophy. The designation provides incentives such as tax credits, fee waivers, and potential seven-year market exclusivity, boosting investor confidence.